ICAN®—International Cancer Advocacy Network

ICAN® is a 501(c)(3) patient advocacy and research advocacy organization with a small staff of professional advocates assisted by hundreds volunteers worldwide. With our volunteer leadership representing 17 different time zones, we literally work around the clock, focusing on our Personalized Medicine Cancer Case Navigation Programs, health information technology issues, legislative initiatives, and research projects.

We aim to provide you with the best patient advocates and the most effective cancer patient advocacy possible, with the twin goals of working to extend your life with the highest quality of life.

ICAN® advocates for you – the patient – or for the patient's spouse or family member who wants to manage the details of their loved one's cancer case with us.

We are beholden to no one – no oncology practice, no medical center, no clinical trial, and no biotech or pharmaceutical company.

Your case is unique and in our many years of non-stop advocacy services, we've never seen two patient cases remotely alike.

ICAN® empowers you to navigate rapidly-expanding diagnostic and personalized treatment options. This information will assist you in informed discussions with family and providers.

We never, ever, compromise patient privacy (zealous implementers of HIPAA) We will not disclose your name or any identifying information, or exploit your case for fundraising purposes.

pie-chart image map EventsLeadershipLegislative IssuesPatient ServicesPhysicians CouncilBiomarkers CouncilScientific Advisory CouncilICAN NewsVolunteersHTML Map

Breaking News!

A New International Research Consortium to Battle Two Rare Cancer Mutations

In April 2016, Kevin Hanlon, an entrepreneur from Syracuse, New York, was diagnosed with an EGFR exon 20 insertion-mutated lung cancer. There are two types of exon 20 insertions, the other is a HER2 insertion. Both are rare gene mutations diagnosed in two percent of non-small cell lung cancer patients. Exon 20 insertions have also been found in 24 other cancers so far. Many of the patients diagnosed with these mutations are, like Hanlon, never-smokers in excellent shape....
— Marcia K. Horn JD, ICAN President and CEO and Exon 20 Group Executive Director

Published in The Future of Health (USA Today Mediaplanet digital supplement on Lung Health). Read the article

Watch a short video clip from Ellrose Hanlon, daughter of Exon 20 Group Co-Founder of cherished memory, Kevin Hanlon

"DART" Clinical Trial—first federally funded NCI dual immunotherapy trial

  Is your tumor PD-L1 amplified by next generation sequencing (NGS)?

We don't mean PD-L1 over-expressing by IHC (immunohistochemistry). We mean PD-L1 amplification which is found by NGS in one out of 150 cancer patients.

Please share the following two journal articles with your oncologist:

  Do you have a Gestational Trophoblastic Disease (GTD)?

  Have you been diagnosed with SCCOHT which is Small Cell Carcinoma of the Ovary--hypercalcemic type?

If you have any of the above cancers, please talk to your oncologist about the open cohorts in the clinical trial of Nivolumab and Ipilimumab in Rare Tumors (the "DART" trial, the first federally funded NCI dual immunotherapy trial).

Many hundreds of trial sites will have openings in each of these three cohorts. Questions? Please us know:

Join the growing community of PD-L1 Amplifieds! ThePDL1Amplifieds@askican.org

Know Your Precise Cancer Diagnosis

Pie chart graphic showing the various percentages of gene mutations-alterations identified in NSCLC Metastatic Lung Cancer - see text only link for complete alt text

If your oncologist cannot tell you what molecular subtype of cancer you have, then you may not have a specific diagnosis yet. And your surgical or biopsy tissue might not have been adequately profiled if your physician did not order comprehensive biomarker testing. Here's a pie chart, created by the brilliant Jacqulyne ("Jackie") Robichaux, PhD, member of the John V. Heymach, MD, PhD Laboratory and Assistant Professor at The University of Texas MD Anderson Cancer Center, which reveals the molecular subtypes of Non-Small Cell Lung Cancer. If you know your particular molecular subtype, treatment decisions will likely be more targeted. If comprehensive biomarker testing does not reveal a specific molecular subtype, then that's also important information for you and your oncologist to have.

Expand Chart InfoGraphic or select (PPTX) (Text Only) (JPG)

ASCO 2021 - Visual Data

Avisual exploration of data presented at ASCO 2021 Virtual Meeting

A visual exploration of data presented at ASCO 2021 Virtual Meeting—LARVOL VERI

Watch the Video (mp4)

Guidestar Platinum Seal of Transparency 2021

Federal Tax I.D.: EIN 86-0818253

This website provides information about ICAN® Personalized Medicine Cancer Case Navigation Programs, while it also describes the ICAN® multi-faceted mission, unique vision, and respected values. Intended for use by the general public. This site also offers more in-depth information for target populations who may benefit from ICAN® Program Services such as ICAN® patients, their caregivers and medical teams — along with those healthcare professionals and researchers who are involved with ICAN® medical and scientific councils.

The health news displayed on this site are chosen by our team of M.D.s, PhDs, and ICAN® President and CEO, who is an Affiliate Member of ASCO, the American Society of Clinical Oncology; AMP, the Association for Molecular Pathology; and AACR, the American Association for Cancer Research. Information contained herein is therefore not intended to substitute for or supersede any advice that a patient receives from his/her health professional and is not intended to compromise in any way the patient-physician relationship. ICAN® strongly believes that all medical decisions need to be made, via shared decision-making, by the patient and his/her medical team.